Recent Updates
Recently added Catalysts
GRI Positive Sentiment Score: 70/100

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

Key Takeaway: GRI Bio, Inc. announced that its CEO, Marc Hertz, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025. The company is focused on developing therapies to treat inflammatory, fibrotic, and autoimmune diseases, primarily through the modulation of Natural Killer T cells. Its lead program, GRI-0621, aims to provide a novel oral treatment for idiopathic pulmonary fibrosis, addressing a critical unmet medical need. The company boasts a diverse pipeline and a significant proprietary compound library.

Market Sentiment Analysis

POSITIVE FACTORS

  • GRI Bio is advancing an innovative pipeline targeting autoimmune diseases.
  • The CEO will showcase the company's therapies at a notable healthcare event.
  • The lead program GRI-0621 addresses a significant unmet need in treating idiopathic pulmonary fibrosis.
  • The company has a robust library of over 500 proprietary compounds.

Full Press Release Details

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET
LA JOLLA, CA, May 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 21, 2025 at 2:40 PM ET.
Click here to register for the event. A live webcast of the fireside chat will be accessible on the Events page under the Investors section of the Company’s website (gribio.com).
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

Tags

Annual Healthcare Company
biotechnology company

Frequently Asked Questions

What is GRI Bio focused on?

GRI Bio specializes in developing NKT cell modulators for inflammatory and autoimmune diseases.

When is Marc Hertz's fireside chat scheduled?

Marc Hertz's fireside chat is on May 21, 2025, at 2:40 PM ET.

How does GRI Bio treat diseases?

GRI Bio targets NKT cell activity to interrupt disease progression and restore immune balance.

What is GRI-0621?

GRI-0621 is GRI Bio's lead program, an inhibitor for treating idiopathic pulmonary fibrosis.

What types of NKT cells does GRI Bio study?

GRI Bio studies type I invariant NKT cells and type 2 diverse NKT agonists.

Last updated: May 16, 2025